3rd world congress on ovulation induction & ovarian stimulation protocols
Ovarian Stimulation Protocols
-
Upload
hesham-gaber -
Category
Health & Medicine
-
view
57.769 -
download
0
Transcript of Ovarian Stimulation Protocols
OVULARIAN STIMULATION PROTOCOLS
Ovulation Induction
Monofollicular development Multifollicular development Complications Novel protocol
Ovulation Induction
Monofollicular development Multifollicular development Complications Novel protocol
Clomiphene Citrate
Dose: 50-100 mg./day. starting day 2,3,4 or 5 for 5 days. Monitoring: ultrasound BBT, LH kits day 21 progesterone.
Unexplained Infertility
CC appears to improve pregnancy rates in women with unexplained subfertility
Meta-analysis by Hughes et al, 2000
Anovulatory cycles
Clomiphene citrate (all doses) was associated with an increased pregnancy rate per treatment cycle
Meta-analysis by Hughes et al, 2000
hCG vs. LH monitoring
If normoovulatory (e.g male factor), LH monitoring is preferred
If ovulatory dysfunction: hCG is preferred
Meta-analysis by Kosmos et al, 2007
CC Resistant
If still anovulatory after 6 months of continuous use the case is considered “clomiphene resistant”
No ovulation:
dose. duration of treatment (10 days). add hMG.
Tamoxifen
No significant benefit of Tamoxifen over CC
Meta-analysis by Stiener et al, 2005
Combination therapies
CC and other agents (metformin, NAC) can be used in CC resistant cases.
Alternative strategies for the CC-resistant woman include : ovarian drilling
So what do we use in Practice?
Clomiphene Citrate
TI AIH
hMG or FSH
______________________________________________hMG or FSH
Ovulation Induction
Monofollicular development Multifollicular development Complications Novel protocol
Your Aim should be .. ..
PROTOCOL
RESULTS
COMPLICATIONS
BEST
Most SUITABLE
AVOID
IVF / ICSI cycles
Multifollicular development with
gonadotropin administration is still an
integral component for ovarian stimulation in
IVF / ICSI cycles
Gonadotrophins
hMG, FSH, rec-FSH
+GnRHa
-long-short-u-short +GnRH
antagonist
Always LP++
IVF ICSI
Protocols for IVF GnRH AntagonistGnRH AntagonistProtocolsProtocols
GnRH GnRH AgonistAgonistProtocolsProtocols
225 IU per day225 IU per day(150 IU Europe)(150 IU Europe) Individualized Dosing of FSH/HMGIndividualized Dosing of FSH/HMG
250 250 g per day antagonistg per day antagonist
Individualized Dosing of FSH/HMGIndividualized Dosing of FSH/HMG
GnRHa 1.0 mg per day GnRHa 1.0 mg per day up to 21 daysup to 21 days 0.5 mg per day of GnRHa0.5 mg per day of GnRHa
225 IU per day225 IU per day(150 IU Europe)(150 IU Europe)
Day 6Day 6of FSH/HMGof FSH/HMG
DayDayof of hCGhCG
Day 1 Day 1 of FSH/HMGof FSH/HMG
Day 6Day 6of FSH/HMGof FSH/HMG
DayDayof hCGof hCG
7 – 8 days7 – 8 daysafter estimated ovulationafter estimated ovulation
Down regulationDown regulation
Day 2 or 3Day 2 or 3of mensesof menses
Day 1 Day 1 FSH/HMGFSH/HMG
OCP
Starting dose
Depends on Age, weight
Usually 3 amp / day in average weight women between 28-35 ys
GnRH-a protocols:
down regulation of the pituitary gonadotrophic function
This will allow prevention of premature LH surge, until full oocyte maturity can be reached.
Short (flare up protocol):
GnRH-a is started on day one or two of the cycle.
Exogenous FSH administration, then is started on day 3 of the cycle to continue follicular stimulation, meanwhile complete pituitary desensitization occur.
Advantages of short protocol
1) 1. Shortening the stimulation time.2) 2. Reducing the amount of GnRH
used.3) 3. Reducing the amount of hMG used.
Thus the total cost of the procedure will be lower.
The protocol was criticized for being unphysiological, and increases the LH levels in the early stages of the follicular phase, which might be harmful to the growing follicles.
The long protocol
GnRH-a is given for two to three weeks. Down regulation of the pituitary gland is achieved as confirmed by the very low level of serum E2.
The GnRH is usually started in the mid luteal phase or early in the early follicular phase.
hMG therapy is started after down regulation
Disadvantages of long protocol
It is more expensive takes longer time. Larger dose of GnRH analogue larger number of ampoules of hMG
A meta analysis of 22 randomized trials comparing long and short protocols demonstrated the superiority of the long protocol of GnRH agonist regarding clinical pregnancy rate.
(Daya 1999)
Ultra-short protocol
GnRHa is given for only three days with the flare up technique
LH could be suppressed till the mid cycle This protocol will help to retrieve more
oocytes with a minimal risk of premature LH surge.
Ultra-long protocol
GnRH could be given for three months before the start of hMG.
May be used in patients with severe endometriosis before the start of the treatment
Pregnancy rate appears to be improved in this sub-group of patients. (Sallam et al, 2004)
Protocols for poor responders Long protocol with large doses of
gonadotropins Clomiphene / hMG / antagonist protocol
Type of Gonadotropin
/ / / 3% glycoproteins
97% other proteins
FSH 75 I.ULH 75 I.U.+ detectableamountsof hCG
Recombinant FSH Batch to batch consistency Free from urinary proteins Can be produced in limitless quantities
In 1995 € 5.0 million
volume increased by <100%
In 2000 € 26.8million
Zwart-van Rijkom et al,2002
Concerns Price
Impact of high cost The decision to adopt a more expensive
treatment could result in a lower number of
cycles of IVF/ICSI treatment especially if
patients are paying for it.
LH supplementation: is it needed!!
Lisi et al., 2001Filicori et al, 2001Westergaard et al., 2001Tesarik and Mendoza, 2002Commenges-Ducos et al, 2002
Schats et al,2000
Balasch et al, 2001
Daya 2002
Balasch et al, 2003
Efficacy
Should be based upon most up to date evidence
RCTs are considered the gold standard
Most important outcome
Live birth rate Per
woman
Effectiveness
Meta-analysis of: Truly randomized controlled trials IVF/ICSI cycles
Al-Inany et al, 2005
Live Birth / Ongoing Pregnancy rate
O.R.: 1.21 (95% CI 0.95-1.54)
Significant result with Long Protocol
O.R.: 1.26 (95% CI 1.00-1.60)
NNT
23
How to Explain!!
LH was shown to improve the implantation rateGordon et al, 2001 Ganirelix dose-finding study ,1998 Schoolcraft et al, 1999
How To ExplainGnRH agonist down-regulation may result in profound suppression of LH concentration (< 1 IU/l) , impairing adequate oestradiol synthesis
Fleming et al, 2000
Agonist vs antagonist
ongoing pregnancy/ live-birth rate
O.R = 0.82, 95% CI = 0.69 to 0.98
Pregnancy per woman
O.R = 0.80, 95% CI = 0.69 to 0.92
The absolute treatment effect (ATE) was calculated
to be 4.5%.
number needed to treat (NNT) 22
This means That
for every 22 subfertile couples undergoing IVF/ ICSI program, one additional pregnancy can be expected in the GnRH agonist treated group
Incidence of OHSS
R.R. = 0.61, 95% CI = 0.42 to 0.89
No difference
Spontaneous miscarriage Rate Multiple pregnancy rate
In Favor of Antagonist
much shorter duration of GnRH analogue treatment (OR -20.90, 95% CI -22.20 to -19.60)
less days of stimulation (OR -1.54, 95% CI -2.42 to -0.66).
reduction in the amount of gonadotrophins (OR -4.27, 95% CI -10.19 to 1.65)
The Future
Prevention of severe OHSS in women downregulated with GnRH agonist and with high risk of OHSS
(GnRH) antagonists
A unique Idea Administration when follicle reach 16 mm Continue hMG (step down protocol) Monitor by E2 Not more than 3 days
Luteal Phase Support
Micronised Progesterone tablets Oral: 100-200 mg 2-4X/day Vaginal: 100-200 mg 2X/day Rectal: 100-200 mg 2X/dayProgesterone Sup. 200-400 mg vag. or rectally 1-2X/dayProgesterone gel (8%)
IM Progesterone 100 mg 1x/day
Ovulation Induction
Monofollicular development Multifollicular development Complications Novel protocol
Complications of Ovulation Stimulation Drugs.
OHSSMultiple Gestation
OHSS.
-large fragile ovaries.-haemoconcentration-oliguria-ascites-pleural effusion
Complications of Ovulation Stimulation Drugs.
OHSSPrevention of
TI/IUI
withhold hCG use “coasting”
use Antagonist
IVF
Complications of Ovulation Stimulation Drugs.
4-folds higher incidence of twins & HRMGMultiple Gestation
Ovulation Induction
Monofollicular development Multifollicular development Complications Novel protocol
Reversed hMG/CC
HP-hMG 75 IU starting from the 3rd day of
cycle for four days.
Followed by 50 mg of CC (Clomid,
Aventis Pharm) three times daily starting
from the fourth day of hMG and continued
until the day of hCG injection.
Novel protocol
75 IU/HMG
CD3 CD7
150 mg CC
hCG IUI
DF ≥ 18 mm
34-36h
Control group
75 IU/HMG
CD3 hCG IUI
DF ≥ 18 mm
CD7
34-36h
Results (cont.)Variable HMG/CC
(n=110)
HMG
(n=107)
P value
LH on day of hCG (miu/ml) for cases
with no premature LH surge
7.3 ± 1.8 7.8 ± 2.2 NS
Number of Follicles ≥ 16 mm 2.4 ± 0.97 1.3 ± 1.1 P < 0.05*
Number of patients with premature LH
surge
6 (5.45%) 17 (15.89%)P<0.001*
End. Thickness (mm) 5.9 ± 0.7 4.9 ± 1.9 NS
Clinical Pregnancy 11 (10%) 9 (8.41%) NS
For whom
This protocol is especially suitable for
young women, for those with
unexplained infertility or mild male factor
i.e good responders
it may also be suitable for PCOS women
to avoid the risk of severe OHSS
This is a novel protocol for OI
The protocol is simple, safe and appears
to be very cost effective.
Take Home Message
Monofollicular development: CC Multifollicular development :
hMG/agonist Complications: OHSS Novel protocol: hMG / CC
THANK YOU